Covid-19 roundup: 34 AGs call for ‘march-in’ rights on remde­sivir; Hahn pleads with pub­lic to trust FDA's vac­cine ...

6 days ago
Coronavirus

No­vo Nordisk ax­es 2 more obe­si­ty drugs as lead­ing drugs 'raise the bar'; Div­ing deep­er in­to R&D, CSL adds sup­port for ...

6 days ago
Protocols

Roche-backed Dicer­na push­es in­to the pack rac­ing to­ward the block­buster hep B goal line, armed with PhI da­ta

6 days ago
R&D

Ver­sant funds TCR ther­a­py biotech T-knife's $78M+ Se­ries A to boost hu­man­ized T cell mice plat­form

6 days ago
Venture
Startups

FDA ap­proves GSK's BC­MA drug, mark­ing a rocky re­turn to can­cer for the British gi­ant

6 days ago
R&D
Regulatory

Lund­beck sounds taps on an­oth­er CNS drug, re­treat­ing from a mine field still oc­cu­pied by a Mer­ck team

6 days ago
R&D

RA, No­var­tis back Gen­tiBio's seed round, plans to launch de­vel­op­ment of En­gTreg ther­a­pies

Last week
Venture

Stem cell play­er Vi­a­Cyte ex­pands col­lab­o­ra­tion with Gore to de­vel­op sub­cu­ta­neous di­a­betes treat­ment

Last week
Deals

Less than 3 months af­ter launch, the AveX­is crew’s Taysha rais­es $95M Se­ries B. Is an IPO next?

Last week
Venture
Startups

My­ovant lands a fresh $200M loan as FDA mar­ket­ing de­ci­sion looms; Amarin goes it alone in Eu­rope

Last week
Protocols

Mod­er­na CEO Stéphane Ban­cel out­lines a prospec­tive moth­er­lode of Covid-19 vac­cine rev­enue — will a back­lash ...

Last week
Coronavirus

Ver­sant de­buts Ridge­line's start­up #4, armed with $30M and al­ter­na­tive TCR cell ther­a­pies for sol­id tu­mors

Last week
Venture
Startups

Covid-19 roundup: J&J and BAR­DA agree to $1 bil­lion for 100 mil­lion dos­es; Plas­ma re­duces mor­tal­i­ty by 50% — ...

Last week
Coronavirus

CF Foun­da­tion, Long­wood team on new in­cu­ba­tor for com­pa­nies with cut­ting-edge CF treat­ments

Last week
Venture
Cell/Gene Tx

FDA touts ad­vanced man­u­fac­tur­ing to ad­dress Covid-19 short­falls

Last week
Regulatory
Coronavirus

Deep tech, round 2: DCVC Bio bags $350M fund to chase the tip of the life sci­ence spear

Last week
Venture

No­vavax her­alds the lat­est pos­i­tive snap­shot of ear­ly-stage Covid-19 vac­cine — so why did its stock briefly crater?

Last week
Coronavirus

Karuna and In­cyte scrap pro­grams; More cash for the SPACs

Last week
Protocols

No­var­tis says Kym­ri­ah reach­es pri­ma­ry end­point in new PhII, al­though num­bers still to come

Last week
R&D

Covid-19 roundup: FDA com­mis­sion­ers call for more ‘con­cert­ed ef­fort’ on con­va­les­cent plas­ma R&D; Re­gen­eron boosts ...

Last week
Coronavirus

Ab­b­Vie shrugs off $134M cash deals, quit­ting a neu­ro R&D pact with Voy­ager Ther­a­peu­tics on vec­tor­ized an­ti­body ...

Last week
R&D

Mer­ck scoops up a PhII J&J dis­card in a bar­gain-base­ment deal. And this time they’re shoot­ing at NASH

Last week
Deals
R&D

Cure­Vac nabs a top No­var­tis sci­en­tist for CSO slot as mR­NA vac­cines seize the spot­light

Last week
People

OWS' Mon­cef Slaoui lam­basts ‘in­sult­ing’ me­dia cov­er­age: 'How are you help­ing in this pan­dem­ic?'

Last week
Coronavirus
First page Previous page 123456 Next page Last page